Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir PET Imaging in Healthy, MCI, and AD Subjects
NCT02016560Phase 3Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Dec 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of flortaucipir in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (4 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline at 18 months, Cross-sectional Flortaucipir Imaging Results and 1 more. Started Dec 2013; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02016560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016560.